Californian company Synthego has raised $110m from Founders Fund, one and Menlo Ventures. Synthego, which supplies genetically-engineered cells to researchers, will use the funding to expand its offerings. The company initially plans to create CRISPR kits, which can be used to develop specific genetic lines, and to develop “clinical-grade” materials, said CEO Paul Dabrowski. Both are part of the firm's ultimate goal of helping to make gene therapies as readily available as vaccines.
Californian company Synthego has raised $110m from Founders Fund, 8VC and Menlo Ventures. Synthego, which supplies genetically-engineered cells to researchers, will use the funding to expand its offerings. The company initially plans to create CRISPR kits, which can be used to develop specific genetic lines, and to develop “clinical-grade” materials, said CEO Paul Dabrowski. Both are part of the firm's ultimate goal of helping to make gene therapies as readily available as vaccines.